Why the study?
Does dual antiplatelet therapy reduce stroke recurrence in adult patients with acute noncardioembolic ischemic stroke or TIA compared to monotherapy?
Does dual antiplatelet therapy reduce stroke recurrence in adult patients with acute noncardioembolic ischemic stroke or TIA compared to monotherapy?
Early dual antiplatelet therapy significantly reduces the risk of early recurrent stroke and composite cardiovascular events compared to monotherapy in patients with acute noncardioembolic ischemic stroke or TIA, without a significant increase in major bleeding.
No takes yet. Share an insight, caveat, or question.
Supports early dual antiplatelet therapy after acute noncardioembolic stroke or TIA; reinforces pooled trial evidence of benefit without excess major bleeding.
Wong et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: